Advertisement

Why VYNE Therapeutics Stock Is Crashing Today

Why VYNE Therapeutics Stock Is Crashing Today

Shares of VYNE Therapeutics (NASDAQ: VYNE) were crashing 18.1% lower as of 11:35 a.m. EDT on Thursday. VYNE reported Q1 revenue of $4.1 million, up from $1.8 million in the prior-year period. VYNE launched Zilxi in October 2020 after receiving approval earlier that year by the U.S. Food and Drug Administration (FDA) for the drug in treating rosacea.